PhD defence Wannes D'Hertog

June 2, 2010
Congratulations to Wannes D'Hertog on the successful defense of his PhD thesis, “Beta-cell death and survival in models for type 1 diabetes: proteomic analysis.” We gratefully acknowledge the promoters and jury members for their expertise and contributions: Chantal Mathieu (promoter), Liliane Schoofs (co-promoter), Lutgart Overbergh (co-promoter), Guido Verhoeven (chairman; Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium), Patrick Callaerts (secretary; Laboratory of Behavioral and Developmental Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium), Piero Marcetti (Clinical and Experimental Medicine, University of Pisa, Pisa, Italy), Etienne Waelkens (Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, Leuven, Belgium), and Peter Hellings (Experimental Immunology, KU Leuven, Leuven, Belgium).
Share this post

PhD Research Summary - Dr. D'Hertog

Type 1 diabetes is an autoimmune disease in which insulin-producing beta cells are selectively destroyed. In his PhD thesis, “Beta-cell death and survival in models for type 1 diabetes: proteomic analysis,” Dr. Hertog explored how proteins change during beta-cell stress and destruction.

Using two-dimensional difference gel electrophoresis, she mapped beta-cell proteins and studied their responses to death-inducing cytokines (IL-1β and IFN-γ) and endoplasmic reticulum stress. His work revealed protective and destructive protein pathways, including roles for the transcription factors STAT-1 and IRF-1 in cytokine-induced beta-cell death. These findings provide new insights into the molecular mechanisms underlying beta-cell vulnerability and may inform future therapeutic strategies for type 1 diabetes.

More information can be found via the link.

Support us

Choose to make a direct impact by contributing to a specific research project or by supporting the overarching goals of the Hippo & Friends Type 1 Diabetes Fund. 

By donating today, you enable early-career scientists to pursue groundbreaking research aimed at preventing and curing type 1 diabetes.
Every contribution moves us one step closer to breakthroughs that matter.